secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001193125-25-253636
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China
--------------------------------------------------------------------------------

- Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.
- Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.
- Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/0001193125-25-253636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/vor-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-253636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer